MANIFEST: Multiomic Platform for Cancer Immunotherapy.

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Cancer immunotherapy has improved patient survival rates.
• Current limitations include a lack of reliable biomarkers for predicting treatment response and toxicity.
• There is a critical need for tools to personalize immunotherapy decisions.

Purpose of the Study:

• To introduce a novel, tumor type-agnostic platform for deep patient profiling in immunotherapy.
• To enable the integrative identification of biomarkers for immunotherapy response and toxicity.
• To discover novel therapeutic targets using advanced computational methods.

Main Methods:

• Development of the Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity (MANIFEST) platform.
• Application of artificial intelligence and machine learning for data analysis.
• Deep profiling of patients undergoing immunotherapy.

Main Results:

• The MANIFEST platform facilitates comprehensive analysis of multi-omic data.
• The platform enables the identification of potential biomarkers for immunotherapy outcomes.
• Initial findings suggest the potential for discovering new therapeutic targets.

Conclusions:

• The MANIFEST platform addresses the unmet need for immunotherapy biomarkers.
• This approach holds promise for personalizing cancer treatment and improving patient outcomes.
• Further validation and application of the platform are warranted.